225Ac-labeled anti-EGFR antibody drug radioconjugate elicits durable anti-tumor responses in mouse models of colorectal cancer

被引：0
|
作者：
Tikum, F. [1 ]
Henning, N. [1 ]
Doroudi, A. [1 ]
Ketchemen, J. [1 ]
Babeker, H. [1 ]
Njotu, F. [1 ]
Monzer, A. [1 ]
Nwangele, E. [1 ]
Uppalapati, M. [1 ]
Gray, B. [1 ]
Torlakovic, E. [1 ]
Fonge, H. [1 ]
机构：
[1] Univ Saskatchewan, Saskatoon, SK, Canada
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-674
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [31] An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
    Chen, Xin
    Xue, Liu
    Ding, Xiao
    Zhang, Jing
    Jiang, Lei
    Liu, Sha
    Hou, Hongjia
    Jiang, Bin
    Cheng, Liang
    Zhu, Qing
    Zhang, Lijie
    Zhou, Xiaosui
    Ma, Jie
    Liu, Qi
    Li, Yucheng
    Ren, Zhiying
    Jiang, Beibei
    Song, Xiaomin
    Song, Jing
    Jin, Wei
    Wei, Min
    Shen, Zhirong
    Liu, Xuesong
    Wang, Lai
    Li, Kang
    Zhang, Tong
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [32] A Fc-competent anti-human TIGIT blocking antibody BGB-A1217 elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models.
    Chen, Xin
    Xue, Liu
    Ding, Xiao
    Liu, Qi
    Zhang, Jing
    Jiang, Lei
    Liu, Sha
    Hou, Hongjia
    Zhu, Qing
    Jiang, Bin
    Zhang, Lijie
    Zhou, Xiaosui
    Ma, Jie
    Li, Yucheng
    Jin, Wei
    Wei, Min
    Shen, Zhirong
    Liu, Mike
    Li, Kang
    Zhang, Tong
    CANCER RESEARCH, 2021, 81 (13)
  • [33] Anti-tumor activity of RYZ101 (Ac-225 DOTATATE) in somatostatin receptor-expressing preclinical models of small-cell lung cancer
    Han, Guangzhou
    Hwang, Eunmi
    Lin, Fanching
    Clift, Renee
    Kim, Daniel
    Bischoff, Eric
    Moran, Susan
    Li, Gary
    CANCER RESEARCH, 2023, 83 (07)
  • [34] Enhancing anti-tumor responses in triple-negative breast cancer by combining SIRP α inhibition with immunogenic chemotherapy or antibody-drug conjugates
    Ma, Xingru
    Tsao, Li-Chung
    Wang, Tao
    Liu, Cong-Xiao
    Gajda, Melissa
    Yang, Xiao
    Lei, Gangjun
    Wei, Junping
    Hartman, Zachary
    CANCER RESEARCH, 2024, 84 (06)
  • [35] MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC
    Furuuchi, Keiji
    Rybinski, Katherine
    Fulmer, James
    Moriyama, Tomoyuki
    Drozdowski, Brian
    Soto, Allis
    Fernando, Shawn
    Wilson, Kerrianne
    Milinichik, Andrew
    Dula, Mary Lou
    Tanaka, Keigo
    Cheng, Xin
    Albone, Earl
    Uenaka, Toshimitsu
    CANCER RESEARCH, 2022, 82 (04)
  • [36] Potent anti-tumor activity of ABN202 ( anti-EGFR antibody-interferon-beta mutein) through direct cytotoxicity and indirect immune activation against non-small cell lung cancer, regardless of EGFR mutation status
    Park, Hee Geon
    Cho, Sung Hun
    Park, Ha Yeon
    Jo, Mi Gyoung
    Park, Ji Hyun
    Seo, Myeung Ryun
    Kim, Ji Hyun
    Hong, Sung Youl
    Song, Kyoung
    Lee, Chan Gyu
    Jeong, Hae Min
    Lee, Sae Hyung
    Kim, Na Young
    Choi, Jun Young
    Shin, Young Kee
    CANCER RESEARCH, 2024, 84 (06)
  • [37] Successful Cetuximab Therapy After Failure of Panitumumab Rechallenge in a Patient with Metastatic Colorectal Cancer: Restoration of Drug Sensitivity After Anti-EGFR Monoclonal Antibody-Free Interval
    Akito Hata
    Nobuyuki Katakami
    Naoto Kitajima
    Journal of Gastrointestinal Cancer, 2014, 45 (4) : 506 - 507
  • [38] Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models
    Naoto Kunimura
    Koichi Kitagawa
    Ryota Sako
    Keita Narikiyo
    Shoko Tominaga
    Diosdado S. Bautista
    Wei Xu
    Masato Fujisawa
    Toshiro Shirakawa
    Scientific Reports, 10
  • [39] Combination of rAd-p53 in situ gene therapy and anti-PD-1 antibody immunotherapy induced anti-tumor activity in mouse syngeneic urogenital cancer models
    Kunimura, Naoto
    Kitagawa, Koichi
    Sako, Ryota
    Narikiyo, Keita
    Tominaga, Shoko
    Bautista, Diosdado S.
    Xu, Wei
    Fujisawa, Masato
    Shirakawa, Toshiro
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [40] Zebrafish patient tumor-derived xenograft models synergize with mouse-PDX models for understanding variation in anti-cancer drug responses
    Ali, Zaheer
    Vildevall, Malin
    Nilsson, Anna
    Schueler, Julia
    Fahlgren, Anna
    De Jensen, Lasse
    CANCER RESEARCH, 2020, 80 (16)
12345